Tirzepatide: PERCEPTIONS survey findings

Most of what we know about tirzepatide comes from Phase 3 trials: tightly controlled environments with strict eligibility criteria and protocol-mandated follow-up. What we know far less about is why real patients actually start the drug, and what they experience once they do. The PERCEPTIONS survey, published in Obesity Pillars in June 2026, is one of the first attempts to answer those questions in a US real-world population^[1].

Who was in the study

The study enrolled 518 adults in the United States between June and November 2025. Participants had obesity or overweight and had recently initiated tirzepatide. The group skewed female (78.2%), mostly White (69.5%), with a mean age of 46 years and a mean BMI of 38.4 kg/m². Nearly half had previously tried and not maintained weight loss through diet and exercise alone before starting treatment. About 12.7% had prior exposure to semaglutide^[1].

That profile is worth holding in mind when reading the findings. This is not a clinical-trial population selected for adherence and low comorbidity. These are ordinary patients in a health system where access to obesity treatment is uneven.

Why they started treatment

The most common reason for starting tirzepatide was improving overall health and wellness: 83.8% of respondents cited this as a motivator. Improving physical functioning came second at 58.3%. Boosting self-confidence and appearance was selected by 51.4%^[1].

These motivators are worth noting because they are not primarily cosmetic. The majority framing is health-first, which aligns with how obesity medicine has shifted over the past decade. The SURMOUNT-1 trial, the pivotal Phase 3 study that underpins the obesity indication, enrolled patients with at least one weight-related comorbidity for that reason: the regulatory and clinical logic is that weight loss matters because of what weight does to health, not because of appearance^[2].

The barrier that overshadowed everything

Treatment cost and insurance coverage were the dominant barriers. Roughly 57.7% of participants flagged cost as a concern. Insurance coverage issues affected approximately 90% of participants at some point in the process^[1].

That figure is consistent with broader reporting on GLP-1 class access in the United States, where list prices run several hundred dollars per month and coverage varies sharply by payer and plan design. The FDA approved tirzepatide for chronic weight management under the brand name Zepbound in November 2023. Coverage for the obesity indication has been patchier than coverage for the type-2 diabetes indication (Mounjaro), and that gap shows up directly in patient surveys.

How patients found the device

On the practical side, the findings were positive. Among participants using the autoinjector pen, 98.0% found the device straightforward to use. Among those using the vial-and-syringe presentation, 95.8% said the same^[1].

Device usability rarely makes headlines, but it matters for adherence. If a patient finds the administration format difficult, the chance of early discontinuation rises. The SURMOUNT-4 trial showed that participants who stopped tirzepatide after an initial weight-loss phase regained a substantial proportion of that weight, which underscores why staying on treatment matters for outcomes^[3].

Disease burden at baseline

The survey captured baseline measures of physical functioning, psychological well-being, and internalized weight bias. Participants reported meaningful impairments across all three. That baseline burden matters for interpreting the access findings: people facing insurance coverage problems while also carrying the psychological load of obesity are in a harder position than the headline enrollment numbers suggest^[1].

What the survey does not tell us

Surveys like PERCEPTIONS have limits worth naming. The population is self-selected: people who agree to fill out a survey may differ from people who start tirzepatide and then disengage from care. The US-only framing means the insurance-access picture is specific to that system, and conclusions do not transfer directly to countries with different payer structures. The study captures reasons for initiation and early experience, not long-term adherence or weight outcomes.

The data also does not capture the full arc of patient experience. What the drug does for psychological burden over time, whether cost barriers lead to early discontinuation, and how outcomes differ between people who got insurance coverage and those who paid out of pocket are questions for follow-up research.

What this adds

Real-world surveys add something that clinical trials cannot: the texture of how a treatment lands in ordinary practice. The PERCEPTIONS data suggests that people who start tirzepatide in a real health system are largely health-motivated rather than appearance-motivated, face meaningful access barriers, and find the drug easy to administer once they obtain it. That is a useful baseline for anyone interpreting adoption data, adherence rates, or the gap between trial efficacy and real-world effectiveness.

For prescribing information on tirzepatide in the US, the FDA-authorised label is held by Mounjaro (DailyMed) for type-2 diabetes (approved 2022) and by Zepbound for weight management (approved November 2023)^[4].

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any treatment decision. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide or pharmaceutical product.